Coluracetam

Last Updated: September 28 2022

Coluracetam (MKC-231) is a racetam drug purported to be a cognitive enhancing drug. It is able to preserve choline uptake into neurons when they are otherwise impaired, but currently there is no evidence for inherent nootropic effects.

Coluracetam is most often used for

Summary

Coluracetam (MKC-231) is a synthetic racetam drug purported to be a nootropic compound. It does not have a large body of evidence investigating it, but the mechanisms of action (as well as structure) appear to be very distinct from other racetam compounds like Piracetam or Aniracetam.

Coluracetam appears to interact with a process known as high affinity choline uptake (HACU for short), which is the rate-limiting step of drawing choline into a neuron for synthesis into the neurotransmitter acetylcholine. Increasing the HACU rate appears to increase the activity of cholinergic neurons, so it is a desired target for cognitive enhancement.

Interventions in rats (as there is no human evidence currently) support the usage of coluracetam at very low oral doses to preserve HACU that is otherwise impaired by the use of research drugs that are known to impair HACU. The limited evidence looking at the inherent effects of coluracetam on the HACU of normal neurons has failed to find any significant interaction.

Coluracetam has also been noted to associate with choline transporters physically, but it is not known exactly what it does once associated.

Overall, there is currently insufficient evidence to support the usage of coluracetam for cognitive enhancement. Further studies are needed to see if it has a therapeutic role in instances where HACU may be impaired (such as Alzheimer's disease).

What else is Coluracetam known as?
Note that Coluracetam is also known as:
  • MKC-231
  • BCI-540
  • 2-(2-oxypyrrolidin-1-yl)-N-(2 3-dimethyl-5 6 7 8-tetrahydrofuro(2 3-b)quinolin-4-yl)acetoamide
Dosage information

The animal research on coluracetam uses an oral dose of 300-3,000mcg/kg bodyweight, which is roughly translated into a human dose of 48-480mcg/kg or (for a 150lb person) 3.2-32.7mg overall.

It appears to have very rapid kinetics, with a peak in blood at around 30 minutes and on the decline within 3 hours. Due to this, supplementation may be time-dependent in relation to activity.

Join our supplement information course

Enter your email for a FREE five-day course on supplements. Get only the information that’s 100% backed by science. We take an independent and unbiased approach to figure out what works (and what’s a waste of time and money).

Examine is the only 100% independent company in the nutrition and supplement industry. While everyone else sells supplements and works with sponsors, we exclusively analyze research.

    The only 100% independent company. While everyone sells supplements, we only analyze research.

    Don't miss out on the latest research

    Become an Examine Insider for FREE to stay on top of the latest nutrition research, supplement myths, and more

      References
      1.^Takashina K, Bessho T, Mori R, Kawai K, Eguchi J, Saito KMKC-231, a choline uptake enhancer: (3) Mode of action of MKC-231 in the enhancement of high-affinity choline uptakeJ Neural Transm.(2008 Jul)
      4.^Yamamura HI, Snyder SHHigh affinity transport of choline into synaptosomes of rat brainJ Neurochem.(1973 Dec)
      5.^Rodríguez-Puertas R, Pazos A, Zarranz JJ, Pascual JSelective cortical decrease of high-affinity choline uptake carrier in Alzheimer's disease: an autoradiographic study using 3H-hemicholinium-3J Neural Transm Park Dis Dement Sect.(1994)
      8.^Fisher A, Mantione CR, Abraham DJ, Hanin ILong-term central cholinergic hypofunction induced in mice by ethylcholine aziridinium ion (AF64A) in vivoJ Pharmacol Exp Ther.(1982 Jul)
      9.^Takashina K, Bessho T, Mori R, Eguchi J, Saito KMKC-231, a choline uptake enhancer: (2) Effect on synthesis and release of acetylcholine in AF64A-treated ratsJ Neural Transm.(2008 Jul)
      12.^Morris BJ, Cochran SM, Pratt JAPCP: from pharmacology to modelling schizophreniaCurr Opin Pharmacol.(2005 Feb)